Drug development in pemphigoid diseases

Katja Bieber, Ralf J. Ludwig*

*Corresponding author for this work


Pemphigoid diseases are organ-specific autoimmune diseases of the skin and/or mucous membranes. They are caused by autoantibodies targeting adhesion molecules located at the dermal–epidermal junction. While the diagnostics of pemphigoid diseases and insights into their pathogenesis have improved significantly, the development of novel treatments that are effective and safe remains an unmet medical need. However, numerous pre-clinical studies and early clinical trials have recently been launched. This review summarizes some pathways leading to drug development in pemphigoid diseases, namely: (i) hypothesis-driven drug development; (ii) omics-based drug development; (iii) drug repurposing; (iv) screening-based drug development; and (v) drug development based on careful clinical observations. Ultimately, it is hoped that this will lead to personalized and curative treatments.

Original languageEnglish
Article numberadv00055
JournalActa Dermato-Venereologica
Issue number5
Pages (from-to)108-114
Number of pages7
Publication statusPublished - 12.02.2020

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)


Dive into the research topics of 'Drug development in pemphigoid diseases'. Together they form a unique fingerprint.

Cite this